# LifeSync Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lifesync

- Industry: Medical Devices & Equipment
- Headquarters: Fort Lauderdale, US
- Website: www.lifesynccorp.com
- Total disclosed funding: $17M
- Latest round: Series A (Jan 8, 2007)
- Investors on record: 4

## About

LifeSync Corporation is a leading provider focused on the design and manufacturing of essential medical cables and leadwires for patient monitoring and neurodiagnostics, serving healthcare providers and medical device manufacturers.Founded in 2000, LifeSync Corporation operates out of Fort Lauderdale, US, and specializes in medical cables and leadwires. The company's operations do not indicate any changes in strategy or business structure. The CEO, Bob Buehler, has a history in the medical devices industry, although further information on prior ventures is not disclosed. LifeSync has participated in 3 deals to date, with the latest funding round being a Series A in February 2025, through which it raised USD 17.20 mn from investors including BVM Capital, Janus Henderson Investors, MPM BioImpact, and Sterling Capital Funds. This amount constitutes the total funds raised by the company.LifeSync specializes in the design and manufacturing of medical cables and leadwires, positioning itself as a vertically-integrated single-source provider of patient monitoring connections. Their core product offerings include precise lead wires for cardiac monitoring, reliable supplies for muscle and nerve tests, essential electrodes for brain monitoring, advanced tools for surgical neuro monitoring, and quality accessories for sleep diagnostics. LifeSync serves a diverse client base that includes hospitals, medical device manufacturers, and healthcare providers, targeting markets such as North America, Europe, and parts of Asia, where efficient patient monitoring systems are crucial.LifeSync operates on a B2B model, generating revenue primarily through the sale of medical cables, leadwires, and neuromonitoring connections to healthcare providers and medical device manufacturers. They establish pricing structures based on product specifications and bulk order agreements, facilitating partnerships that standardize monitoring equipment while managing costs. Flagship products include radiolucent ECG leads and specialized electrodes tailored for neurodiagnostic applications, ensuring compliance with healthcare industry standards.In February 2025, LifeSync Corporation was acquired by Amphenol, which aims to leverage LifeSync's capabilities to expand into high-growth medical and connectivity markets, reinforcing its commitment to innovation. The recent funding will support initiatives including the development of new product lines and potential expansion into additional geographic markets, although specific regions and timelines have not been disclosed. LifeSync's strategic direction under Amphenol is to enhance its product offerings and market reach.

## Funding rounds

- Series A, Jan 8, 2007, $17M — BVM Capital, MPM BioImpact, Janus Henderson Investors, Sterling Capital Funds

## Investors

- BVM Capital (https://capitalatlas.ai/funds/bvm-capital) — Series A
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A
- Janus Henderson Investors — Series A
- Sterling Capital Funds — Series A